Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas Sells 6,404 Shares of Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 6,404 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $10,950.84. Following the sale, the senior vice president now owns 587,848 shares in the company, valued at approximately $1,005,220.08. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Allogene Therapeutics Price Performance

ALLO stock opened at $1.64 on Thursday. The stock has a market capitalization of $343.86 million, a P/E ratio of -1.05 and a beta of 0.83. Allogene Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $5.78. The business has a fifty day moving average price of $2.05 and a 200-day moving average price of $2.45.

Institutional Investors Weigh In On Allogene Therapeutics

Large investors have recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of Allogene Therapeutics by 101.5% during the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after buying an additional 172,745 shares during the period. Zacks Investment Management purchased a new stake in Allogene Therapeutics during the third quarter valued at $1,446,000. Geode Capital Management LLC lifted its holdings in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after acquiring an additional 407,070 shares during the period. Dimensional Fund Advisors LP boosted its position in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after purchasing an additional 507,021 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Allogene Therapeutics by 70.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock valued at $1,119,000 after purchasing an additional 198,231 shares during the period. 83.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ALLO shares. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler dropped their price target on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.73.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).